In This Section

Klarissa Jackson

Current position

Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy

Degrees/Institutes

  • BS, Chemistry, Jackson State University, 2006
  • PhD, Pharmacology, Vanderbilt University, 2011
  • Postdoctoral Fellowship, University of Washington, 2013

ASPET member since: 2013

Administrative Accomplishments

I previously served as Councilor for the Drug Metabolism and Disposition Division (DMDD) Executive Committee of ASPET (2019-2022). In this role, I participated in quarterly meetings with the DMDD Executive Committee, I served as an abstract reviewer and judge for the student and postdoc poster competition at the ASPET annual meeting, I served as a reviewer for the Gillette Award for best paper, and I participated in the Meet the Experts Lunch. I also served as a member of the ASPET Mentoring and Career Development Committee (2019-2022), in which I provided input on programming opportunities to support student, postdoc, and early faculty career development. In addition, I have served as an ad-hoc reviewer for the Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section and as a reviewer for Drug Metabolism and Disposition and other journals in the field.

Research Areas

The overarching mission of my research program is to understand the underlying mechanisms of interindividual variability in drug metabolism and toxicity in ethnically diverse and understudied ancestry populations. My laboratory is currently investigating the roles of cytochromes P450 and non-P450 enzymes in the metabolism and toxicity mechanisms of tyrosine kinase inhibitors and cannabidiol. A major focus of our work is on defining the genetic and non-genetic factors that influence drug metabolism and bioactivation and that may contribute to the risk for developing drug-induced liver injury. My laboratory is also engaged in translational research to investigate phenotypic biomarkers of cytochrome P450-mediated drug metabolism for use in clinical and translational studies. The long-term goals of this research are to improve the prediction of serious adverse drug reactions and to apply innovative translational approaches to maximize drug efficacy and minimize drug toxicity for the individual patient.

ASPET Activities

  • Drug Metabolism and Disposition Editorial Advisory Board
    • Member (2022 – present)
  • ASPET Fellows Review Committe
    • Committee Member (2022 – present)
  • ASPET Division for Drug Metabolism and Disposition, Executive Committee
    • Councilor (2019 – 2022)
  • ASPET Mentoring and Career Development Committee
    • Committee Member (2019 – 2022)
  • ASPET Teaching Institute Symposium
    • Co-Chair (2015)

Other Society Memberships/Activities

  • International Society for the Study of Xenobiotics (ISSX)
    • Member
  • American Chemical Society (ACS)
    • Member

 

 


Last Updated: November 29, 2022

Job Postings